ReviewEuropean journal of nuclear medicine and molecular imaging2020
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
Review in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Immunogenic cell death as a mechanism of synergy between sunitinib andCell death discovery · 2026Article
- Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.European journal of nuclear medicine and molecular imaging · 2026Review
- Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.EJNMMI research · 2025Article
- Targeted Treatment of Cancer by Using Conjugate Compounds with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.ACS medicinal chemistry letters · 2025Article
- Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.Cancers · 2024Article
- Investigation of Photodynamic Therapy Promoted by Cherenkov Light Activated Photosensitizers-New Aspects and Revelations.Pharmaceutics · 2024Article
- Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.Theranostics · 2024Review
- Heterogeneous SSTR2 target expression and a novelFrontiers in oncology · 2024Article
- Signaling Network Response to α-Particle-Targeted Therapy with theJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Article
- Dosimetry in Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy.Cancers · 2022Article
- Review
- Optimizing the Schedule of PARP Inhibitors in Combination withBiomedicines · 2021Article
- Combination Therapies with PRRT.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy ofCancers · 2021Article
- Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).Therapeutic advances in medical oncology · 2021Review
- Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.Molecules (Basel, Switzerland) · 2020Review
- Enhancing the anti-tumour activity ofScientific reports · 2020Article
- Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.Current topics in medicinal chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic options are limited because diagnosis is often delayed until the tumour has metastasized. Peptide receptor radionuclide therapy (PRRT) is among the most effective therapeutic options for metastatic NETs because of targeted delivery of radioactivity to the tumour via the somatostatin receptor (SSTR) and relatively low systemic toxicity. However, current PRRT regimes result in palliation rather than cure, and higher doses of PRRT that might achieve remission would also be too toxic to the patients. Therefore, there is a need to improve PRRT of NETs by combining it with other agents to achieve maximum benefits from the internal radiation therapy, while sparing non-target organs from radiation toxicity. Here we review various current and potential combination strategies to improve
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.